Trastuzumab is in the United States by Genentech

Trastuzumab is in the United States by Genentech, in Japan by Chugai and internationally by Roche. Since 1998, trastuzumab used to used to treat nearly 600,000 patients with HER2-positive breast cancer worldwide .

– Stage III colon cancer – a monotherapy as adjuvant therapy after surgery – metastatic colorectal cancer – monotherapy – in combination with any chemotherapy in all lines of treatment – Advanced Gastric cancer – In combination with platinum-based chemotherapy primarily – locally advanced or metastatic breast cancer – monotherapy primarily in patients after failure of taxanes and an anthracycline-containing chemotherapy or for anthracycline therapy is not indicated – in combination with docetaxel in patients after failure of cytotoxic chemotherapy.

Roll Call at Wyoming Sen. Mike Enzi hope for cross-party calls: he financial committee negotiator and senior member of Health, Education, Labor and Pensions panel displays its support for the healthcare reform in part testified at his ability to collect to gather to support seventy-five to eighty Senate this condition by others Finance chief negotiator Chuck Grassley , high-level the committee a member will shared.

get information